NVO vs SENS
NVO: A global healthcare leader driving innovations to defeat diabetes, obesity, and other serious chronic diseases. SENS: Senseonics develops implantable continuous glucose monitoring systems that stay under the skin for up to one year, offering diabetes patients longer intervals between sensor replacements than conventional CGM devices.
Side-by-side fundamentals
| Metric | NVO | SENS | Edge |
|---|---|---|---|
| Price as of 2026-08-10 close | $47.73 | $7.54 | |
| Market cap as of 2026-08-11 | $209.1B | $399M | |
| P/E as of 2026-08-11 | 11.61 | n/a | |
| PEG as of 2026-08-11 | 16.16 | -0.27 | SENS lower |
| Net margin as of 2026-08-11 | +35.4% | -214.2% | NVO higher |
| Gross margin as of 2026-08-11 | +80.7% | +52.1% | NVO higher |
| Operating margin as of 2026-08-11 | +43.1% | -212.9% | NVO higher |
| ROE as of 2026-08-11 | +59.1% | -130.0% | NVO higher |
| ROA as of 2026-08-11 | +21.1% | -67.2% | NVO higher |
| Debt / equity as of 2026-08-11 | 0.63 | 1.05 | NVO lower |
| Revenue growth (YoY) as of 2026-08-11 | +5.6% | +71.9% | SENS higher |
| Revenue CAGR (3y) SEC XBRL | +20.4% | +29.1% | SENS higher |
| Dividend yield as of 2026-08-11 | +3.8% | n/a | |
| Beta as of 2026-08-11 | 1.92 | 1.03 | |
| 1-year return as of 2026-08-10 close | -6.6% | -23.8% | NVO higher |
Fundamentals: market data, as of 2026-08-11. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-10.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.